Podcasts about regulatory

Send us a textBob Hankins brings over 20 years of dedicated experience in the medical-device industry, spanning engineering leadership, product development, process improvement and strategic technical oversight. As Director of Engineering at TE Connectivity, he leads a global team of engineers and scientists focused on designing, developing and delivering innovative customer-centric medical device solutions—particularly complex machined, extruded and laser-cut components. In this role he ensures design for manufacturing and quality within ISO 13485-compliant systems, marrying deep technical understanding with regulatory-driven manufacturing discipline.Before his current role Bob led Research & Product Development Engineering at Nordson Medical and has held key leadership positions at several medical-device companies, including overseeing product development platforms, multi-site engineering operations, manufacturing automation and system launches. Throughout his career he has honed core competencies in manufacturing process improvement, continuous improvement (including Six Sigma/Lean methodologies), design for manufacturing/assembly, regulatory compliance (ISO 13485, ISO 14971, FDA), and product R&D for the health-care market.Bob's academic background includes a Bachelor of Science in Mechanical Engineering from the University of California, Irvine, and an Executive MBA from the Drucker School at Claremont Graduate University. This combination of technical and business education supports his ability to lead engineering organizations in bridging innovation with operational execution, customer development and quality.In this episode we'll dive into how Bob thinks about leading engineering teams in the regulated medical-device space, how he drives design and process improvements globally, how he balances innovation with manufacturing rigor, and what advice he has for engineers growing into leadership roles in healthcare technology. We'll also explore his views on what the next wave of medical-device manufacturing and design looks like—and how engineering leaders can foster a culture of excellence, empowerment and impact. LINKS:Guest LinkedIn: https://www.linkedin.com/in/rthankins/Guest website: https://www.te.com/en/home.html Aaron Moncur, hostThe Wave is  a place for engineers to actively learn, share ideas, and engage with people doing similar work. Learn more at thewave.engineer Subscribe to the show to get notified so you don't miss new episodes every Friday.The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment such as cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us on the web at www.teampipeline.us Watch the show on YouTube: www.youtube.com/@TeamPipelineus

In this episode, we break down how Uber Freight posted flat Q4 results but finally achieved breakeven profitability through disciplined cost measures. We also discuss the company's pivot toward autonomous trucking as a long-term strategy to drive higher asset utilization. On the asset-based side, we analyze why losses continue at Heartland Express as the carrier navigates costly fleet integrations and a soft market. Despite recording its tenth consecutive net loss, the company's improving operating margins offer a glimmer of hope for a turnaround. Regulatory news takes center stage as the EPA targets truck engine makers to investigate widespread DEF system failures causing "limp mode" incidents. This major shift aims to treat equipment reliability as a manufacturer quality issue rather than a driver compliance problem. Global instability forces the Gemini Alliance to rely on military forces to secure Red Sea voyages, even as other carriers continue to divert around Africa. Back home, the industry faces a bureaucratic paradox where 65,000 new visas are available but remain inaccessible due to a State Department freeze. Finally, we examine the broader economic fallout as weak freight demand triggers facility closures and layoffs across the logistics and manufacturing sectors. With over 3,000 jobs cut since mid-January, the industry is questioning how much leaner operations can get. Follow the FreightWaves NOW Podcast Other FreightWaves Shows Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, the hosts dissect a high-revenue, fast-scaling precious metals buyer that might be both a goldmine and a landmine—complete with potential regulatory issues, cash-heavy operations, and lending red flags.Business Listing - https://dashboard.dealforce.com/deals/profiles/Profile69159.pdfWelcome to Acquisitions Anonymous – the #1 podcast for small business M&A. Every week, we break down businesses for sale and talk about buying, operating, and growing them.Looking to build a professional website in minutes? Try Wix: https://wix.pxf.io/c/6898629/3115214/25616?trafcat=templateHubSpot is the backbone for how businesses scale without chaos. Try them out here: https://go.try-hubspot.com/OeG9Vr

A Note from Michael: The Thriving Farmer Podcast is currently on pause as we navigate a busy season on the farm. While we're taking this break, we're excited to share Farm in Focus, a special series of short, focused conversations recorded earlier this year. These bite-sized episodes highlight practical insights from farmers and experts across the industry. We hope they're helpful and encouraging as you continue your farming journey. What does it really take to run a small, year-round local market? In this Farm in Focus episode, Michael sits down with Emma de Long of Kneehigh Farm to talk about the creation and day-to-day operation of Red Dog Market, a year-round local food market in Pennsylvania. Emma shares how Red Dog Market grew out of increased demand during the COVID-19 pandemic and how it has evolved into a community-centered outlet for her farm and other local producers. From staffing and sourcing to signage, POS systems, and regulatory considerations, Emma offers a candid look at the realities behind keeping fresh food accessible all year long. Whether you're considering opening a farm store, expanding into retail, or simply curious about the behind-the-scenes work of local food markets, this episode offers practical, grounded insights from someone doing it every day.   In this episode, you'll hear about: The Origin of Red Dog Market • How COVID-19 accelerated demand for local food access [02:42] • Why Kneehigh Farm serves as the market's anchor vendor [02:42] Market Operations & Staffing • Running a year-round market with a small, focused team [08:32] • The role of a dedicated market manager and daily task division [08:32] • Why maintaining fresh produce is "a puzzle every day" [14:39] Sourcing & Vendor Relationships • How Emma vets vendors—especially for meat and dairy products [12:25] • The importance of building strong relationships with local producers [05:34] • Balancing product variety with quality and consistency [12:25] Systems, Marketing & Logistics • The complexities of using POS systems for a small, hybrid market model [14:39] • Effective signage and in-person marketing strategies [16:51] • Leveraging existing farm share and CSA memberships to build traffic [16:51] Advice for Aspiring Market Owners • Why starting slow and understanding your costs is critical [16:51] • Regulatory considerations every market owner should be aware of • How community engagement shapes long-term success [20:40] Bio: Emma de Long is a farmer, educator, and fiber advocate based in Chester County, Pennsylvania. She founded Kneehigh Farm in 2013 and has since grown a diverse mix of vegetables, dye plants, and fiber crops. Since 2019, Emma has cultivated indigo for natural pigment extraction, and in 2020 she co-founded the Pennsylvania Flax Project, an initiative dedicated to rebuilding regional flax processing infrastructure. Kneehigh Farm operates as a 100% women-run operation, and in 2021 Emma opened Red Dog Market, a year-round outlet for farm goods and local products. Links:

The freight recession may finally be over as January transportation metrics reveal a market in firm expansion territory. With the overall index hitting 59.6, a convergence of tightening capacity and rising rates suggests the cycle has officially turned. Regulatory pressures are squeezing the driver pool just as Werner Enterprises settles an 11-year-old lawsuit regarding driver wages. This $18 million payout underscores the rising floor for labor costs in an increasingly constrained environment. On the demand side, a surge in Japanese machine tool orders points to a manufacturing rebound later this year. North American orders jumped nearly 30%, signaling that industrial production is gearing up for a strong second half of 2026. Macroeconomic policy could also provide a tailwind if Fed Chair nominee Kevin Warsh shifts focus back to Main Street. His criticism of current monetary strategy suggests relief may be on the way for the industrial and small business sectors. Meanwhile, rail infrastructure is booming with Norfolk Southern customers advancing over $7.7 billion in new projects. Adding to the positive momentum, legal distractions are clearing up for major players following the dismissal of charges against NFI's CEO. Follow the FreightWaves NOW Podcast Other FreightWaves Shows Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome back to the markets after a brutal weekend. Gold just had its worst day since 1983, crashing 9%, while silver fell a staggering 27%—the largest drop ever recorded. Add to that steep declines in copper and oil, and we've got the recipe for a volatile open. Meanwhile, Asian equities got crushed, with the KOSPI down 5%, and China's manufacturing PMI missed badly. In Europe, green shoots: France and the UK posted surprise PMI gains, while Germany's retail sales shocked to the upside. In crypto, BTC fell to $74K before rebounding, with more than $5.5B in liquidations since Thursday. Regulatory talks begin today at the White House, while Ripple secures a full EU license. The week is off to a chaotic start—catch the full breakdown inside.

In this episode, Lynn Hamilton speaks with Stuart Goodall, Senior Vice President at Syneos Health, about how regulatory functions are evolving in response to growing complexity, accelerating timelines and emerging technologies. With more than 35 years of global experience, Stuart offers an unfiltered perspective on what regulatory and medical writing teams need to succeed today—and how to scale smartly for what's next. Topics explored include:·      The shift from information advantage to decision advantage in regulatory intelligence·      How AI is changing—not replacing—medical writing and regulatory operations·      What sponsors need to consider when building scalable, tech-enabled models·      Why FSP is no longer just transactional and how strategic partnerships are redefining value·      Why storytelling and judgment remain irreplaceable in an automated world Whether you're exploring your next medical writing solution or rethinking regulatory infrastructure, this conversation offers grounded insights with a forward-looking lens.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this episode of the Consumer Finance Monitor Podcast, we examine one of the most closely watched and increasingly controversial developments in consumer finance: earned wage access (EWA) products. EWA products allow workers to access a portion of wages they have already earned before their scheduled payday. Proponents describe these products as a valuable financial tool that helps consumers manage cash-flow shortfalls without resorting to traditional payday loans. Critics, including the Center for Responsible Lending (CRL), argue that EWA products function as high-cost credit, often involving opaque fees that can trap consumers in cycles of debt. Our panel brings together industry and advocacy perspectives to explore the research, legal arguments, and regulatory uncertainty surrounding EWA, a market that has grown rapidly but remains unevenly regulated. Meet the Speakers ·        Alan Kaplinsky – Host and moderator. Founder and former Practice Group Leader of Ballard Spahr's Consumer Financial Services Group; now Senior Counsel. ·        Lucia Constantine – Senior Researcher at the Center for Responsible Lending, focusing on mortgage lending and predatory debt practices. ·        Yasmin Farahi – Deputy Director of State Policy and Senior Policy Counsel at CRL, specializing in small-dollar lending and state consumer protection initiatives. ·        Joseph Schuster – Partner in Consumer Financial Services Group at Ballard Spahr, with extensive experience advising on earned wage access products and their legal and regulatory treatment. Key Topics Covered in the Episode ·        What Is Earned Wage Access? An overview of EWA products, how they operate, and why they have become a focal point for regulators and consumer advocates. ·        Consumer Protection vs. Industry InnovationCRL presents research suggesting that EWA products operate as high-cost credit and may contribute to debt accumulation, while industry participants argue the products provide needed liquidity and differ fundamentally from traditional loans. ·        Fees, Tips, and Consumer Understanding A discussion of common pricing models, including expedited access fees and voluntary "tips," and whether consumers fully understand the true cost of using EWA services. ·        Research Findings CRL reviews studies conducted by it based on anonymized transaction data indicating frequent repeat usage, escalating fees, and increased overdraft activity among some users. ·        The Regulatory and Legal Landscape An examination of ongoing litigation, divergent state approaches, and federal regulatory ambiguity. While some states regulate EWA as credit, others have carved out exemptions. Courts are increasingly being asked to determine whether EWA products constitute "loans" under existing law. ·        Industry Responses and SafeguardsDiscussion of non-recourse structures, voluntary fee models, and industry-led efforts to mitigate consumer harm. ·        Policy Outlook Consideration of congressional interest, state-level reform efforts, and the likelihood of future regulatory intervention. Why This Episode Matters The debate over earned wage access is still in its early stages, but the outcome will have significant implications for fintech providers, employers, consumers, and regulators. This episode provides essential context and analysis for financial services professionals seeking to understand how EWA fits within existing consumer credit frameworks, and how that framework may change. Consumer Finance Monitor is hosted by Alan Kaplinsky, Senior Counsel at Ballard Spahr and founder and former chair of the firm's Consumer Financial Services Group. We invite you to subscribe on your preferred podcast platform for weekly insights into key developments in consumer financial services law and regulation. Since its recording, there have been a few developments relevant to this episode. For instance, on December 22, 2025, the Consumer Financial Protection Bureau issued an advisory opinion that states the Truth In Lending Act (TILA) does not apply to certain "earned wage access (EWA) products," and it rescinds a proposed interpretive rule issued under former CFPB Director Chopra that classified these products as credit subject to TILA with their fees considered finance charges. The Center for Responsible Lending expressed opposition to this latest advisory opinion. On January 13, 2025, the House Financial Services Committee held a hearing on financial technology that included consideration of draft legislation on "Earned Wage Access," which CRL refers to as "payday loan apps." Around 200 nonprofits have written to Congress about their opposition to the version of this bill as introduced last session of congress.

In this episode of the Epigenetics Podcast, we talked with Peggy Farnham from the Keck School of Medicine at USC about her work on establishing the ChIP Method in mammalian cells. In this episode, we dive into the relationship between transcription factors, chromatin dynamics, and gene expression with Professor Peggy Farnham from the Keck School of Medicine at USC. Professor Farnham shares her profound insights into how her groundbreaking research has reshaped our understanding of gene regulation and its implications in cancer. We explore how she has been a pioneer in mapping the genome-wide landscape of regulatory proteins, illuminating the molecular logic behind transcriptional control and its disruption in cancer biology. The interview starts with her instrumental role in adapting chromatin immunoprecipitation (ChIP) technology from yeast to human cells. Professor Farnham reflects on the technical challenges she faced during this transition, such as the quest for visibility of signals in mammalian systems. Her ability to innovate and troubleshoot challenges led to significant advancements in techniques that allow for the rapid identification of transcription factor binding sites, fundamentally changing the landscape of epigenetic research. As the discussion progresses, we learn about Professor Farnham's active involvement in the ENCODE project, where she contributed to high-resolution mapping of transcription factors and regulatory elements in human cells. She articulates her appreciation for collaborative efforts in science, highlighting how working within a consortium harnesses the collective expertise of diverse research groups. This collaboration not only bolstered the credibility of the data produced but also propelled the field forward in understanding the complexity of gene regulation. Through her participation in various projects, such as the Psyc-ENCODE consortium and the Roadmap Epigenome Mapping Consortium, Professor Farnham shares insights into her investigation of epigenetic variations, particularly in relation to complex disorders like schizophrenia. Her findings underscore the nuances of enhancer variability among individuals and the implications for understanding disease mechanisms, thereby advancing our knowledge of genetic regulation and its contributions to diverse biological outcomes. Moreover, the episode highlights Professor Farnham's reflective understanding of emerging technologies in the field. She discusses the evolution of methods that allow researchers to investigate gene regulation at single-cell resolution, recognizing the significant implications these innovations have for our comprehension of cellular differentiation and the transcriptional landscape. References Weinmann AS, Bartley SM, Zhang T, Zhang MQ, Farnham PJ. Use of chromatin immunoprecipitation to clone novel E2F target promoters. Molecular and Cellular Biology. 2001 Oct;21(20):6820-6832. DOI: 10.1128/mcb.21.20.6820-6832.2001. PMID: 11564866; PMCID: PMC99859. Wells J, Farnham PJ. Characterizing transcription factor binding sites using formaldehyde crosslinking and immunoprecipitation. Methods (San Diego, Calif.). 2002 Jan;26(1):48-56. DOI: 10.1016/s1046-2023(02)00007-5. PMID: 12054904. Rhie SK, Schreiner S, Witt H, et al. Using 3D epigenomic maps of primary olfactory neuronal cells from living individuals to understand gene regulation. Science Advances. 2018 Dec;4(12):eaav8550. DOI: 10.1126/sciadv.aav8550. PMID: 30555922; PMCID: PMC6292713. Tak YG, Hung Y, Yao L, et al. Effects on the transcriptome upon deletion of a distal element cannot be predicted by the size of the H3K27Ac peak in human cells. Nucleic Acids Research. 2016 May;44(9):4123-4133. DOI: 10.1093/nar/gkv1530. PMID: 26743005; PMCID: PMC4872074. Related Episodes The Effect of lncRNAs on Chromatin and Gene Regulation (John Rinn) CpG Islands, DNA Methylation, and Disease (Sir Adrian Bird) The Future of Protein–DNA Mapping (Mitch Guttman) MLL Proteins in Mixed-Lineage Leukemia (Yali Dou) Contact Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com

We are starting 2026 with predictions from several of HRP Associates, top thought leaders. We want to know what they predict for 2026! Once we hear what everyone's predictions are, Brooke, Carly, and Ally join together to talk new year resolution ideas in bingo form!  A reminder that our Play Hard segment is also available in video form! Watch that on our YouTube Channel. Make sure you subscribe, give us a review & check us out on social media!YouTubeLinkedInInstagramTwitterFacebookWebsite

For decades, medical device manufacturers in the US relied on 21 CFR 820 (QSR) — a system known for being procedural and checklist-oriented.But starting February 2nd, 2026, FDA will implement QMSR, changing not only the regulation structure but also the inspection philosophy.QMSR does not eliminate Part 820. Instead, FDA is amending it to incorporate ISO 13485:2016 by reference, bringing the US closer to the global quality language used across Europe, Canada, Japan, and beyond.Why FDA is doing thisFDA's move is driven by three key goals:Harmonization (reduce duplicated systems and audits)Modern quality thinking (move from “procedures” to “system effectiveness and risk”)Inspection efficiency (more end-to-end audits)What inspections may look like under QMSRInstead of jumping between SOPs, inspections may follow real flows like:Complaint → Risk Management → CAPA → Design Change → Supplier ImpactThe focus becomes traceability, consistency, and risk-based justification.What companies should do nowTo be QMSR-ready, companies should:Build an ISO 13485-style process mapMake risk visible everywhere, not only in product developmentImprove CAPA triage and effectiveness checksStrengthen design controls (especially software development & V&V)Train teams on the new “why/how” inspection styleWho is Monir El Azzouzi? Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland. Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more. 

George Mekhail, Managing Director of Bitcoin for Corporations at BTC Inc, explains why Bitcoin is no longer being ignored by institutions — it's being actively challenged.In this interview from the Bitcoin MENA Conference, George breaks down why corporate Bitcoin treasury companies are being targeted, how global corporate adoption is accelerating, the role of advocacy in protecting Bitcoin companies, and whether the traditional four-year Bitcoin cycle still applies.Topics covered include: • Why institutions are pushing back against Bitcoin • Corporate Bitcoin adoption around the world • Regulatory friction in Europe vs the United States • The MSCI proposal targeting Bitcoin-heavy balance sheets • Whether Bitcoin's four-year cycle is changing

Doctronic became the first AI in the world legally licensed to practice medicine through Utah's AI Learning Lab regulatory sandbox in December 2025. In this episode of BUILDERS, I sat down with Matt Pavelle, Co-founder and Co-CEO of Doctronic, to learn how he and his co-founder (a physician) launched an AI-powered primary care chatbot in September 2023, validated demand through Facebook chronic condition groups and minimal Google Ads spend, and navigated uncharted regulatory territory to offer $4 prescription renewals for chronic conditions—targeting the medication non-adherence problem that causes 125,000 preventable deaths and costs $100B annually. Topics Discussed: Why friends with excellent health insurance still couldn't get medical answers quickly Building clinical accuracy into GPT-3.5 when context windows were small and hallucinations were rampant The tactical launch: Google Ads plus Facebook chronic condition groups in September 2023 Architecting safety: RAG with tens of thousands of physician-written clinical guidelines The study: 99.2% agreement rate between AI treatment plans and human doctor reviews across 500 patients Navigating Utah's AI Learning Lab: the only regulatory sandbox that mitigated medical licensing laws Securing AI malpractice insurance through Lloyd's Market—a first in the industry The three-phase oversight model: 100% human review, then 10%, then spot checks Expansion strategy: targeting other state regulatory sandboxes and international governments GTM Lessons For B2B Founders: Launch with the minimum feature set that proves your core hypothesis: Pavelle shipped Doctronic in September 2023 without user accounts—chats disappeared when closed unless users saved them manually. Within days, user requests for persistent chat history validated demand. The insight: your MVP should test one assumption, not solve every user need. If you're hesitating to launch because features are missing, ask whether those features are actually required to validate your hypothesis or just things you assume users want. Use specificity to unlock early adoption in skeptical markets: Rather than targeting "healthcare" broadly, Pavelle posted in Facebook groups for specific chronic conditions, offering a free AI backed by clinical guidelines. Half the groups banned them for commercial activity, but the other half engaged immediately. The lesson: in regulated or skeptical markets, narrow targeting with explicit safety mechanisms (clinical guidelines, physician co-founder credibility) converts better than broad positioning. Identify where your skeptics congregate and address their specific objections upfront. Design system architecture to prevent failure modes, not just tune models: Doctronic's safety architecture separates AI decision-making from prescription execution. The LLM asks questions and determines renewal safety, but deterministic code outside the AI verifies the prescription exists, checks dosage accuracy, and confirms the schedule. Even if adversarial prompting compromises the LLM, the deterministic layer prevents bad outcomes. Founders building high-stakes AI products should architect multiple independent verification layers rather than relying on prompt engineering or temperature tuning alone. Target regulatory pain points with quantified deaths and costs: Pavelle approached Utah with specific numbers: 125,000 preventable deaths annually from medication non-adherence, 30-40% caused by renewal friction, and a $100B economic burden. These statistics—combined with Utah's rural population and physician shortage—made the problem impossible to ignore. When approaching regulators, lead with mortality and cost data that make inaction untenable, not just efficiency gains or convenience improvements. Regulatory sandboxes require proof of safety methodology, not just technology demos: Utah's AI Learning Lab didn't just grant Doctronic permission—they required a three-phase oversight structure where human physicians review 100% of initial prescriptions in each medication class, then 10%, then ongoing spot checks. Pavelle also secured AI malpractice insurance through Lloyd's Market before launch. The insight: regulatory innovation offices want risk mitigation frameworks, not promises. Build and fund your oversight methodology before approaching regulators, and treat insurance underwriting as a third-party validation of your safety claims. Publish clinical validation studies before scaling—they become your regulatory and sales asset: The study showing 99.2% agreement between Doctronic's AI and human physicians across 500 patient encounters became the foundation for regulatory conversations and public trust. Founders in regulated spaces should budget for formal validation studies early—these aren't marketing expenses, they're the permission structure for everything that follows. Work backward from what regulators and enterprise buyers need to see, then design studies that generate that specific evidence. // Sponsors: Front Lines — We help B2B tech companies launch, manage, and grow podcasts that drive demand, awareness, and thought leadership. www.FrontLines.io The Global Talent Co. — We help tech startups find, vet, hire, pay, and retain amazing marketing talent that costs 50-70% less than the US & Europe. www.GlobalTalent.co // Don't Miss: New Podcast Series — How I Hire Senior GTM leaders share the tactical hiring frameworks they use to build winning revenue teams. Hosted by Andy Mowat, who scaled 4 unicorns from $10M to $100M+ ARR and launched Whispered to help executives find their next role. Subscribe here: https://open.spotify.com/show/53yCHlPfLSMFimtv0riPyM

On this special edition of The Data Day podcast, Ropes & Gray partner Rohan Massey—leader of the firm's data, privacy & cybersecurity practice and managing partner of the London office—is joined by counsel Edward Machin and associates Catherine Keeling and Suzie Wilson to celebrate the 19th World Data Protection Day and explore the evolving landscape of data, privacy, and cybersecurity regulation across the UK and EU in 2026. The discussion covers headline-making cybersecurity breaches, new compliance obligations under DORA and the Cyber Resilience Act, and the anticipated UK cyber bill. The panel also examines the regulatory outlook for AI, including key dates for the EU AI Act and the potential direction of the UK's AI Bill. Rounding out the conversation, the team highlights upcoming changes in digital regulation, such as the UK's Data (Use and Access) Act, the EU Data Act, and the Digital Omnibus package.

The logistics sector is sending mixed signals in early 2026, with some data pointing to a boom while other indicators suggest fragility. On the growth side, 3PLs are dominating industrial leasing as corporations aggressively outsource their complex supply chains. Financial metrics back up this optimism, with Triumph Financial reporting rising invoice sizes and the addition of major fleets like J.B. Hunt to their network. This consolidation suggests big players are circling the wagons around platforms that provide stability and value. Operational efficiency is also improving, as C.H. Robinson uses AI agents to automate ready-checks and reduce unnecessary return trips by 42%. These technological advancements are helping stabilize networks by cutting out pure waste like fuel and driver time. However, friction remains in the air cargo sector, where Alaska Airlines is dissatisfied with its Amazon contract due to pilot scheduling issues and thin margins. The airline is looking to renegotiate terms or exit the deal as it struggles to optimize utilization between passenger and cargo operations. Regulatory and geopolitical risks are also mounting, highlighted by a court decision denying a reprieve for non-domiciled CDL renewals in California. Furthermore, global trade lanes face renewed uncertainty after Houthis threatened new attacks in the Red Sea, potentially forcing ships back around the Cape of Good Hope. Follow the FreightWaves NOW Podcast Other FreightWaves Shows Learn more about your ad choices. Visit megaphone.fm/adchoices

On this episode of HALO Talks, host Pete Moore sits down with Hunter Ziesing, founder of Longevity Health, to dive into the rapidly chaing volving world of preventive health and personal wellness data. Bringing decades of experience from Wall Street, athletic pursuits, and nonprofit work, Hunter shares his inspiration for moving into longevity and healthspan solutions after seeing friends and family struggle with preventable health issues. He discusses Longevity Health's mission: Democratizing access to clinical-grade health data and AI-driven recommendations. . . basically what elite practitioners charge six figures for, made accessible to the masses. Learn about how he aims to empower individuals to truly own their health data, integrate information from wearables and medical tests, and leverage AI for personalized action. This episode also explores the business of building scalable solutions, collaborating with fitness chains, and balancing the desire to revolutionize public health with mindful entrepreneurship.  On affordable (preventative!) health care for all, Zasing states, " My mission is to really give people the Peter Attia. You know. . .what he charges $150,000 for, for as little as 30 cents a day." Key themes discussed Leveraging personal health data for prevention and longevity AI integration in health management and recommendations Consumer ownership and use of health data Partnerships with fitness clubs and labs for testing Transition from nonprofit to for-profit health ventures Scaling health platforms through technology and collaborations Challenges and vision for democratizing preventive healthcare A Few Key Takeaways:  1.Data-Driven Personalized Health is the Future: Hunter is building a platform (Longevity Health) that brings together personal health data—from wearables, medical records, blood tests, and more—to help guide individuals in preventative health and wellness. His mission is to democratize access, offering "Peter Attia-level" insights at an affordable price. 2. Behavior Change is Achievable and Measurable: Through previous ventures like the national cycling series supporting Livestrong, and his work at Paceline, Hunter  demonstrated that motivating people with goals, teams, and rewards (even as simple as a dollar for hitting your heart rate target) can create real, lasting behavior change. 3. AI-Powered Recommendations Enhance Preventive Care: The company is beta testing an AI engine that analyzes your consolidated health data, gives personalized recommendations, and will eventually act almost like a virtual doctor. For now, a human clinician still reviews and oversees the AI's conclusions, ensuring safety and accuracy. 4. Consumer Ownership Over Health Data is Key: Both Ziesing and Pete discuss the importance of individuals owning their own health data. Regulatory shifts (even tech giants like Apple and Google are getting behind this) are beginning to empower consumers, rather than siloing data within companies. 5. Partnerships and Integrations Will Drive Scale: Rather than trying to own every piece of the ecosystem, Hunter emphasizes the strategy of partnering with gyms, health clubs, and existing testing providers. The vision is to make Longevity Health the connective "last mile" that ties together disparate data to deliver actionable insight—potentially white-labeling the tech or integrating with large fitness chains for scale. Resources:  Hunter Ziesing: https://www.linkedin.com/in/hunterziesing/ Longevity Health: https://www.longevityhealth.me/  Integrity Square: https://www.integritysq.com Prospect Wizard: https://www.theprospectwizard.com Promotion Vault: https://www.promotionvault.com HigherDose: https://www.higherdose.com

The FCC has extended its waiver of the TCPA's “Revoke All” consent-revocation mechanism and adopted key reforms to the Robocall Mitigation Database rules, including updated requirements for voice service providers and new deadlines for filing attestations and supporting documentation. These changes reflect the FCC's ongoing effort to balance consumer protection from illegal robocalls with practical compliance timelines for providers navigating authentication, mitigation, and traceback obligations. Hosted by Simone Roach. Based on a blog post by Alysa Z. Hutnik and Jennifer Rodden Wainwright.

In this episode of Medsider Radio, we sat down with Marina Pavlovic Rivas, co-founder & CEO of Eli Health.The company is focused on making hormone data accessible in real time through its saliva-based testing system that delivers results through a mobile app. A data scientist by training, Marina previously founded Gradiant AI, a machine learning company that was acquired in 2019. In this interview, Marina discusses how to evaluate form factor options without locking into a design too early, what beta testing reveals that years of lab work can't, and how existing consumer spending patterns influence positioning and pricing strategies. She also shares how regulatory considerations shaped product decisions from the outset and why building in-house proved more efficient than outsourcing when external partners said the company's goals were impossible.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Marina Pavlovic Rivas.

While many of you might have been enjoying the holiday season, thebeat of healthcare keeps on beating.Much has happened in the world of medical coding and that is whythe producers of Talk Ten Tuesday are dedicating the next liveedition of the popular national Internet broadcast to the topic ofcoding.And that's why Dr. James S. Kennedy, a trained medical professionalwho loves coding, will be the Talk Ten Tuesday special guest.The popular Internet broadcast will also feature these additionalinstantly recognizable panelists, who will report more news duringtheir segments:POV: Penny Jefferson, Manager of Coding & Clinical Documentation Integrity Services for the University of DavisMedical Center, is the new cohost of Talk Ten Tuesday. Shewill share her point of view (POV) during the broadcast.The Coding Report: Christine Geiger, Assistant Vice Presidentof Acute and Post-Acute Coding Services for First ClassSolutions, will report on the latest coding news.Social Determinants of Health: Tiffany Ferguson, CEO forPhoenix Medical Management, Inc., will report on the news thatis happening at the intersection of medical record auditing andthe SDoH.CDI Report: Cheryl Ericson, Director of Clinical DocumentationIntegrity (CDI) for the vaunted Brundage Group, will have thelatest CDI updates.The Coding Report: Christine Geiger, Assistant Vice Presidentof Acute and Post-Acute Coding Services for First ClassSolutions, will report on the latest coding news.News Desk: Timothy Powell, ICD10monitor nationalcorrespondent, will anchor the Talk Ten Tuesdays News Desk.

For episode 669 of the BlockHash Podcast, host Brandon Zemp is joined by Matt Carr, Managing Partner of QCI Partners.

While many of you were enjoying the holidays, Kaiser Permanente wasback in the news. This time, another whistleblower case which resulted inan amazing $556 million settlement to resolve allegations that the giantprovider/payer fudged on its Medicare Advantage risk adjustment.Reporting the lead story during the next live edition of Monitor Mondays willbe Liz Soltan, a New York-based senior associate at WhistleblowerPartners. Soltan is a member of the firm's litigation team who representedDr. James Taylor in his landmark False Claims Act (FCA) case againstKaiser Permanente which resolved allegations of Medicare Advantage riskadjustment fraud. Soltan also works on a major Medicare Advantage riskadjustment fraud case against UnitedHealth Group on behalf ofwhistleblower Benjamin Poehling.Broadcast segments will also include these instantly recognizable features: Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM,will be making his Monday Rounds. The RAC Report: Healthcare attorney Knicole Emanuel, partnerat the law firm of Nelson Mullins, will report the latest news aboutauditors. Risky Business: Healthcare attorney David Glaser, shareholderin the law offices of Fredrikson & Byron, will join the broadcast withhis trademark segment. Legislative Update: Adam Brenman, legislative affairs liaison forZelis, will report on current healthcare legislation.

Bitcoin is increasingly being shaped not just by markets, but by policy, as regulators around the world split into six distinct regulatory paths that could dramatically alter adoption, capital flows, and innovation. From Washington's stalled legislation and shifting SEC–CFTC dynamics to global divergence between enforcement-heavy regimes and innovation-friendly frameworks, today's stories highlight a growing reality: regulatory clarity is becoming a competitive advantage.

New @greenpillnet pod out today!

Dr. Kelly Cohen is a Professor of Aerospace Engineering at the University of Cincinnati and a leading authority in explainable, certifiable AI systems. With more than 31 years of experience in artificial intelligence, his research focuses on fuzzy logic, safety-critical systems, and responsible AI deployment in aerospace and autonomous environments. His lab's work has received international recognition, with students earning top global research awards and building real-world AI products used in industry.In this episode 190 of the Disruption Now Podcast,

In this enlightening episode of 90 Miles from Needles, host Chris Clarke explores the intricate world of bees with Mary O' Brien from Project 1100. The conversation delves into the potentially deleterious effects of honeybee apiaries on public lands, a topic that's both counterintuitive and crucial for the public to understand. Honeybees, although often seen as critical to agriculture and ecosystems, can pose significant threats to native solitary bees that have co-evolved with local flowering plants. Mary O' Brien sheds light on how these industrious honeybees outcompete their native cousins, impacting pollination dynamics that are vital for the desert's diverse flora. Listeners will gain valuable insights into the importance of preserving native bee species, the complexities of their ecological roles, and the nuanced implications of honeybee proliferation. O'Brien also shares practical strategies for those interested in conservation, emphasizing the importance of habitat protection and mindful consumerism when it comes to honey and pollinator support. Key Takeaways: Honeybees, although widely supported and utilized in agriculture, can have adverse effects on native bee populations, outcompeting them for resources and spreading diseases. The high reproductive rate of honeybees poses a threat to native plants relying on solitary native bees for pollination, potentially destabilizing ecosystems. Public lands serve as critical refuges for native bee species, which are often overlooked in conventional conservation discussions. Consumers can contribute to bee conservation efforts by choosing their honey responsibly and fostering habitats for native pollinators. Regulatory frameworks around public land usage play a significant role in the sustainability of native bee populations, calling for increased transparency and stakeholder engagement. Notable Quotes: "Trying to save bees by saving the honeybee is like trying to save birds by saving the chicken." "Native bees evolved in tandem with flowers, and honeybees are not very good pollinators of many species of plants." "Once you know native solitary bees are in your world, you really can delight in seeing such diversity." "Public lands are the wildflower repositories for the Western U.S.; especially in the desert." "It's often quite attractive to think that you're buying wildflower honey; however, you're almost certainly buying honey that was produced on public land." Resources: Project 1100 Website Xerces Society for Invertebrate Conservation The Forgotten Pollinators by Stephen Buchmann and Gary Nabhan Common Bees of Western North America laminated guide Center for Biological Diversity resources on pollinators: Bees Pollinators Pollinators in Peril report Discover the intricate dynamics between honeybees and native pollinators and why preserving the biodiversity of our desert ecosystems is more crucial than ever. Listen to the full episode to deepen your understanding of this vital subject and stay tuned to 90 Miles from Needles for more insightful discussions on desert conservation. Podcast episode artwork: Mojave poppy bee (Perdita meconis). Photo courtesy Zach Portman / University of Minnesota Department of Entomology via the Nevada Independent.Become a desert defender!: https://90milesfromneedles.com/donateSee omnystudio.com/listener for privacy information.

Scrip senior editor Jessica Merrill, Scrip US managing editor Mandy Jackson and In Vivo senior reporter David Wild discuss trends and topics from interviews and presentations at the J.P. Morgan Healthcare Conference and Biotech Showcase.

In this episode of Talk Fantasy To Me, Kyle dives into the latest developments in the entertainment industry, focusing on Netflix's acquisition of Warner Bros. and the implications for Hollywood. The discussion covers the potential impact on consumer choice, the future of theatrical releases, and the role of AI in content creation. Kyle also explores Paramount's counter-offer and the broader industry dynamics at play.   Takeaways Netflix's acquisition of Warner Bros. could reshape Hollywood. Paramount's counter-offer adds complexity to the deal. AI's role in content creation is expanding. The future of theatrical releases is uncertain. Consumer choice may be impacted by media consolidation. The entertainment industry is at a crossroads. Regulatory scrutiny is expected for the Netflix deal. Paramount's all-cash offer is seen as superior by some. The merger could lead to significant industry changes. Hollywood's traditional model is being challenged.   Sound bites "Netflix's acquisition could reshape Hollywood." "Paramount's offer adds complexity." "AI is changing content creation." "The future of theaters is uncertain." "Consumer choice is at risk." "Hollywood is at a crossroads." "Regulatory scrutiny is expected." "Paramount's offer is seen as superior." "The merger could change the industry." "Hollywood's model is challenged."   Chapters 00:00:00 Introduction to the Episode 00:03:00 Netflix's Acquisition of Warner Bros. 00:09:00 Paramount's Counter-Offer 00:15:00 AI's Role in Content Creation 00:21:00 Impact on Theatrical Releases 00:27:00 Consumer Choice and Media Consolidation 00:33:00 Regulatory Scrutiny and Industry Changes 00:39:00 Conclusion and Future Outlook    

Escalating distrust in identity systems and misuse of AI are forcing a shift in security accountability for small and midsize businesses. Recent analysis highlights that the prevalence of deepfake-driven business email compromise and non-human digital identities is eroding confidence in traditional protective solutions. According to Techyle and supporting reports referenced by Dave Sobel, the ratio of non-human to human identities in organizations is now 144:1, further complicating authority and responsibility for managed service providers (MSPs). As trust in exclusive third-party control disintegrates, co-managed security models are becoming standard, repositioning decision-making and liability.The rise of AI-generated data—described as “AI slop”—has prompted increased adoption of zero trust models, with 84% of CIOs reportedly increasing funding for generative AI initiatives. However, as rogue AI agents are recognized as a significant insider threat, current security services are often ill-equipped to manage these new vulnerabilities. Regulatory bodies, including CISA, have issued guidance noting that the integration of AI into critical infrastructure introduces greater risk of outages and security breaches, particularly when governance remains ambiguous. High-profile vulnerabilities in open-source AI platforms used within cloud environments further highlight the persistence of operational risks.Adjacent technology updates include new releases from vendors such as 1Password, WatchGuard, JumpCloud, and ControlUp. These offerings focus on enhancing phishing prevention, expanding managed detection and response, and automating endpoint management for MSPs. However, Dave Sobel emphasizes that these tools introduce additional layers of automation and integration without adequately clarifying who ultimately holds authority and accountability when failures or breaches occur. There is a consistent warning that stacking solutions or outsourcing core functions without redefining operational control creates gaps between action and oversight.For MSPs and IT leaders, the key takeaway is that security risk is no longer defined by missing technology but by unclear governance, undefined authority, and misaligned incentives. Without explicit contractual and operational delineation of responsibility when deploying AI and automation, service providers are increasingly exposed to liability by default. The advice is to move beyond tool-centric strategies and focus on process clarity: define who authorizes, audits, and terminates non-human identities; establish which parties approve automation actions; and ensure clients understand shared responsibilities to mitigate silent risk accumulation. Four things to know today00:00 TechAisle Warns SMB Security Will Shift in 2026 as Identity Attacks and AI Agents Redefine Risk05:44 AI Moves Deeper Into Critical Infrastructure as Open-Source and Human Weaknesses Expand the Attack Surface09:35 MSP Security Platforms Automate Phishing Prevention and MDR—Outpacing Governance and Control Models12:12 AI-Powered MSP Tools Promise Control and Efficiency, But Shift Responsibility by Default This is the Business of Tech.    Supported by:  https://scalepad.com/dave/

In this episode of Medsider Radio, we sat down with Greg Walters, co-founder & CEO of Excision Medical. Excision is developing a leaflet modification system to enable lifetime management of aortic stenosis.Greg has almost 40 years of experience in cardiovascular devices, holding leadership roles at Kensey Nash Corporation where he led the development of Angio-Seal and several endovascular programs. He later co-founded Essential Medical, which was acquired by Teleflex in 2018, and is an inventor on more than 75 U.S. and European patents.In this interview, Greg discusses why early-stage teams should build to learn rather than to impress, using functional prototypes to generate real feedback and fundraising momentum. He outlines how disciplined safety work — not perfection — defines first-in-human readiness, and what makes a pre-revenue company attractive to strategic acquirers. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Greg Walters.

In this episode of The Product Experience, host Randy Silver talks with Cristina Bustos, Product Manager and team lead at Swiss AviationSoftware, about her experience launching a native mobile application in one of the most regulated and high‑stakes industries in the world: commercial aviation.Cristina recounts how she moved from business analysis into product leadership and then navigated a gruelling product development process during the pandemic. Her team faced the dual challenge of winning over both paying customers and aviation regulators to replace paper‑based cockpit workflows with a real‑time digital solution.Chapters0:00 | Introduction and personal background 2:34 | Problem framing: launching a mobile app in aviation 4:00 | Winning founding customers before building code 6:10 | Consensus across customers and regulators 9:00 | Involving actual pilots in design 10:00 | Redesigning workflow not just digitising it 14:15 | Scope control and prioritisation 17:16 | Regulatory engagement and approval strategy 19:49 | A hackathon that wasn't a silver bullet 21:06 | Reflections: what she would do differently 25:22 | Balancing iteration with regulatory discipline 28:21 | Triple validate in the real world 29:53 | Signals of success and business impactOur HostsLily Smith enjoys working as a consultant product manager with early-stage and growing startups and as a mentor to other product managers. She's currently Chief Product Officer at BBC Maestro, and has spent 13 years in the tech industry working with startups in the SaaS and mobile space. She's worked on a diverse range of products – leading the product teams through discovery, prototyping, testing and delivery. Lily also founded ProductTank Bristol and runs ProductCamp in Bristol and Bath. Randy Silver is a Leadership & Product Coach and Consultant. He gets teams unstuck, helping you to supercharge your results. Randy's held interim CPO and Leadership roles at scale-ups and SMEs, advised start-ups, and been Head of Product at HSBC and Sainsbury's. He participated in Silicon Valley Product Group's Coaching the Coaches forum, and speaks frequently at conferences and events. You can join one of communities he runs for CPOs (CPO Circles), Product Managers (Product In the {A}ether) and Product Coaches. He's the author of What Do We Do Now? A Product Manager's Guide to Strategy in the Time of COVID-19. A recovering music journalist and editor, Randy also launched Amazon's music stores in the US & UK.

What if the failure rate in clinical trials isn't about picking the wrong drug candidates—but about testing them in the wrong models?When you move cells from a 2D culture plate into a bioreactor, you're not simply scaling volume. You're fundamentally changing the biological context. Cell density shifts. Mass transfer dynamics evolve. Mechanical cues emerge. The cells sense these changes and respond—often in ways that derail strategies built on oversimplified assumptions.Most preclinical research still relies on flat plastic surfaces and animal models that miss critical aspects of human biology. The result? Therapeutics fail late in development because the models couldn't predict how human tissues would actually respond.In this episode, David Brühlmann speaks with Catarina Brito, Principal Investigator at ITQB NOVA and Head of the Advanced Cell Models Laboratory at iBET and ITQB NOVA in Portugal. Catarina's career-defining insight came early: studying glycan-protein interactions in murine versus human cells revealed that species differences weren't just nuances—they were fundamental gaps that could mislead entire research programs.Catarina and her team have developed neural, liver, and tumor models that capture the multicellular complexity and microenvironmental cues that 2D cultures cannot replicate. Her work creates preclinical models sophisticated enough to predict human responses while remaining scalable for drug development workflows.Highlights of the episode:Limitations of traditional 2D cell cultures and animal models in capturing realistic tissue behavior and therapeutic responses (06:27)Catarina Brito's personal scientific journey: from discovering model limitations to pioneering 3D culture systems in neural and liver tissues (04:19)How advanced 3D models recreate cell-to-cell interactions, tissue-specific microenvironments, diffusion gradients, and multicellular complexity (10:35)Regulatory movements toward reducing animal models, and the challenge of validating advanced alternatives for systemic biology studies (09:10)Key differences in designing bioreactors for various cell types, with practical examples from liver and neural models (15:16)The impact of scalable, robust 3D models on accelerating drug development and improving selection of candidate therapies (17:22)Key Takeaway:Bioprocess development starts when you choose the model that validates your therapeutic approach. If that model can't capture the biology that matters, every downstream optimization is built on a flawed foundation.In Part 2, Catarina reveals how 3D tumor microenvironments expose drug resistance mechanisms invisible in 2D cultures, and her vision for AI-powered digital twins enabling personalized medicine.Subscribe & Review:If this conversation changed how you think about preclinical model selection, leave a review on Apple Podcasts. Your reviews help other biotech scientists discover these insights.For more CMC development insights, visit smartbiotechscientist.com.Connect with Catarina Brito:LinkedIn: www.linkedin.com/in/catarina-brito-ibetAdvanced Cell Models Lab – iBET: www.ibet.pt/laboratories/advanced-cell-models-labNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Sarah Halko, Head of Regulatory and Industry Relations at TNS, joined Doug Green, Publisher of Technology Reseller News, for a Cloud Communications Alliance (CCA) podcast focused on the FCC's Do Not Originate (DNO) mandate and its role in combating robocalls and caller ID spoofing. Halko explained that DNO (Do Not Originate) identifies phone numbers that should never be used for outbound calling—such as invalid, unallocated, or inbound-only numbers like government agencies. Blocking calls that spoof these numbers allows service providers to stop obvious fraud earlier in the call path, before it reaches consumers. While DNO began as an optional tool in 2017, regulatory expectations have steadily increased. As of December 15, 2025, every service provider in the call flow must maintain a “reasonable DNO list,” making accurate, up-to-date data essential for compliance. “Without reliable, authoritative numbering data, service providers can't confidently determine which calls should be blocked,” Halko said. “DNO compliance ultimately depends on knowing how numbers are assigned, used, and routed in real time.” TNS supports providers by delivering trusted, continuously updated numbering and routing intelligence across the U.S., Canada, and the Caribbean. This enables earlier, more accurate call blocking and reduces the risk of false positives or missed fraudulent traffic. Looking ahead, Halko emphasized that DNO is only one part of a broader trust framework that also includes analytics, traceback, authentication (STIR/SHAKEN), and Know Your Customer practices—all working together to protect network integrity. Learn more: https://tnsi.com/

This episode is an interview with Aruna Dhontabhaktuni, Founder and CEO of RegKey, a regulatory intelligence platform that uses AI. The discussion touches on how companies can leverage large language model AI tools to accelerate regulatory strategy work.Links discussed in the show:You can contact Aruna by email: arunad@regkey.aiVisit the RegKey website Connect with Aruna on LinkedIn You can connect with Nathan on LinkedIn and send me a message Send Nathan a message Sign up for Nathan's newsletter Copyright Teuscher Solutions LLC

Join us for an exclusive deep dive into the science and new research behind P84 with two of LifeVantage's top research leaders, Lisa Barnes, VP of R&D and Regulatory, and Christina Beer, Director of Research. In this episode, they break down our newest P84 clinical studies in a way that's easy to understand and powerful to share. You'll learn what the research proves, why it matters for your health and your business, and how to confidently talk about the science behind P84 combined with Protandim.  If you've ever wanted to feel more confident explaining why P84 works — this episode is your go-to. Science made simple. Confidence made easy. *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease

In this episode of The Future Conceived, host Cam Schmidt sits down with Dr. Jim Ferrell, Professor of Chemical and Systems Biology at Stanford University. Known for his pioneering work in the logic of cell signaling, Dr. Ferrell discusses the "mechanism" of life through the lens of physics, chemistry, and mathematics.Dr. Ferrell shares his journey from a triple major at Williams College to becoming a leading voice in Systems Biology. The conversation dives deep into:Biological Circuits: How evolution uses motifs like negative feedback and relaxation oscillators to create "all-or-none" switches and rhythmic pulses in cells.The "Blender" Experiment: A fascinating look at how frog egg extracts can self-organize from "homogenized garbage" back into complex, cell-like structures.Quantitative Reasoning: Why thinking like a physicist—using ordinary differential equations and reaction-diffusion models—is essential for moving biology beyond "stamp collecting" and toward a unifying theory of how life builds and repairs itself.Whether you are a trainee or an established researcher, this episode offers a profound perspective on how the integration of physical forces and biochemical activities brings about the events of life.

NHTSA extended Tesla's deadline to respond to an FSD investigation covering 8,313 potential traffic violations. The new February 23 deadline arrives just after Musk announced FSD will become subscription-only on February 14, the same day California's DMV gave Tesla to fix misleading marketing or face a sales ban. We break down what federal regulators are actually investigating, why Tesla is juggling three major probes simultaneously, and how the subscription pivot may be a legal hedge as regulators close in.

To help support the show:CashApp- ⁠https://cash.app/$drchrisloomdphd⁠Venmo- ⁠https://account.venmo.com/u/Chris-Loo-4⁠Buy Me a Coffee- ⁠https://www.buymeacoffee.com/chrisJx⁠Subscribe to our email list: ⁠https://financial-freedom-podcast-with-dr-loo.kit.com/⁠Click here to join PodMatch (the "AirBNB" of Podcasting): ⁠https://www.joinpodmatch.com/drchrisloomdphd⁠Click here to purchase my books on Amazon: ⁠https://amzn.to/2PaQn4p⁠For audiobooks, visit: ⁠https://www.audible.com/author/Christopher-H-Loo-MD-PhD/B07WFKBG1F⁠Disclaimer: Not advice. Educational purposes only. Not an endorsement for or against. Results not vetted. Views of the guests do not represent those of the host or show.  

In this episode, Adam Torres interviews Philip Recht, Partner at Mayer Brown LLP, about takeaways from the Milken Institute Middle East & Africa Summit in Abu Dhabi, the Gulf's rapid push into AI and data centers, and the legal and regulatory issues shaping global investment—from trade and national security to energy, critical minerals, and AI governance. Big thank you to ⁠⁠⁠⁠⁠⁠⁠⁠Milken Institute⁠⁠⁠⁠⁠⁠⁠⁠! About Philip Recht Co-leader of the firm's Public Policy, Regulatory & Government Affairs practice and former managing partner of the firm's Los Angeles office (2009-21), Phil Recht represents clients in legislative, regulatory, enforcement and litigation matters before and involving federal, state and local governments.Co-leader of the firm's Public Policy, Regulatory & Government Affairs practice and former managing partner of the firm's Los Angeles office (2009-21), Phil Recht represents clients in legislative, regulatory, enforcement and litigation matters before and involving federal, state and local governments. About Mayer Brown LLP Mayer Brown is a leading international law firm, positioned to represent the world's major corporations, funds and financial institutions in their most important and complex transactions and disputes. Follow Adam on Instagram at ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/askadamtorres/⁠⁠⁠⁠⁠⁠⁠⁠⁠ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://missionmatters.lpages.co/podcastguest/⁠⁠⁠⁠⁠⁠⁠⁠⁠ Visit our website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://missionmatters.com/ Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode of the Milk Road Show, Coinbase's Head of Institutional Research David Duong breaks down the hidden "backdoor stimulus" that could inject $140 billion into the market, and why the stalling of the Clarity Act might not matter as much as investors fear.~~~~~

Our Global Head of Fixed Income Research Andrew Sheets looks at the implications of the U.S. government's efforts to ease regulations, from bank balance sheets to asset valuations.Read more insights from Morgan Stanley.----- Transcript -----Andrew Sheets: Welcome to Thoughts on the Market. I'm Andrew Sheets, Global Head of Fixed Income Research at Morgan Stanley. Today, a core theme of easing policy, and the latest iteration in the U.S. mortgage market. It's Thursday, January 15th at 2pm in London. Central to our thinking for the year ahead is that we're seeing an unusual combination of easing monetary policy, fiscal policy, and regulatory policy – all at the same time. This isn't normal, and usually this type of support is only deployed under much more dire economic conditions. All this is also happening alongside another large supportive force – over $3 trillion of AI- and datacenter-related spending that Morgan Stanley expects all to happen through the end of 2028. This broad-based easing is a global theme. Equities in Japan have been rallying on hopes of even a larger fiscal leasing in that country. In Europe, we think that Germany will continue to spend more while the European Central Bank and Bank of England cut rates more than the market expects.But like many things these days, it's the United States that's at the heart of the story. We think that the U.S. Federal Reserve will continue to lower interest rates this year, even as core inflation persists above its target. The U.S. government will spend about $1.9 trillion more than it takes in, even after adjusting for tariffs as tax cuts from the One Big Beautiful Bill Act kick in. But my focus today is on the third leg of this proverbial three-legged stimulative stool. While easing monetary and fiscal policy probably get the most focus, easing regulatory policy is another big lever that's being pulled in the same direction. Regulatory policy is opaque, and let's face it can be a little boring. But it's extremely important for how financial markets function. Regulation drives the incentives for the buyers of many assets, especially in the all-important banking and insurance sectors. It can set almost by definition what price an asset needs to trade at to be attractive, or how much of an asset a particular actor in the market can or cannot hold. Regulatory policy tightened dramatically in the wake of the Global Financial Crisis, but now it's starting to ease. Our U.S. bank equity analysts expect that finalization of key capital rules later this year – an important regulatory step – could free up about [$]5.8 trillion – with a T – of balance sheet capacity across the Global Systematically Important Banks. In mid-December, the office of the comptroller of the currency and the FDIC withdrew lending guidelines from 2013 that had discouraged banks from making loans to more highly indebted companies. And just last week, the U.S. administration announced that the U.S. mortgage agencies, Fannie Mae and Freddie Mac would buy [$]200 billion of mortgages to hold on their own balance sheet; a significant move that quickly tightens spreads in this key market. For investors, we see several implications. This simultaneous easing across monetary, fiscal, and now regulatory policy supports a market that runs hot and where valuations may overshoot. And in the specific case of these agency mortgages, my colleague Jay Bacow and our mortgage strategy team think that this shift is now very quickly in the price. Having previously been positive on agency mortgage spreads, they've now turned to neutral. Thank you as always for your time. If you find Thoughts on the Market useful, let us know by leaving a review wherever you listen. And also tell a friend or colleague about us today.

In this episode of FYI – For Your Innovation, ARK's CEO Cathie Wood hosts a wide-ranging conversation with Marco Santori, CEO of Solmate, and Dr. Arthur Laffer, renowned economist and longtime ARK advisor. Together, they explore the evolving crypto landscape, regulatory shifts, and why Solana is emerging as a powerful foundation for next-generation financial infrastructure. Santori, previously Chief Legal Officer at Kraken and General Partner at Pantera, shares why he's now focused on building Solmate atop the Solana blockchain—and why the Middle East is a critical part of that strategy. He explains Solana's technical advantages, from base-layer speed to support for smart contracts, and its potential to become the platform of choice for high-frequency trading, AI-driven transactions, and decentralized financial services. Dr. Laffer brings historical context to the conversation, contrasting private and government-controlled currencies and making the case for innovation in monetary systems. He also reflects on why he joined the board of Solmate and what excites him about its approach to financial infrastructure and economic growth.Key Points From This Episode:●      [0:00] Meet the guests: Marco Santori's legal background and early Solana investment●      [4:45] Regulatory whiplash: How the U.S. landscape shifted under a new administration●      [7:16] Dr. Laffer's crypto “aha” moment and the history of private money●      [13:30] Why Marco chose Solana: performance, smart contracts, and AI readiness●      [18:05] Ethereum vs. Solana: decentralization, speed, and Wall Street applications●      [23:27] Solmate's board and Middle East connections●      [30:14] Why the United Arab Emirates (UAE) is betting on Solana●      [37:09] The evolution of Solmate from digital asset treasury to infrastructure company●      [42:38] Revenue strategy: building cash flow, not just holding tokens●      [46:23] The Middle East as a geographic and latency hub for blockchain innovation●      [51:06] High-frequency transacting: the next frontier in trading●      [52:31] Solana and on-chain prediction markets

We speak with a rose grower about the market and supply for Valentine's Day.Farm Bureau president talks about the cost of regulations sinking farmers.The pear industry seeks relief from a flood of imports.A webinar series for those transitioning to organic farming.

Medboard: https://www.medboard.com/EuropeEMD Mag Issue 3 - For QA RA people: https://easymedicaldevice.com/emd-mag/EU to simplify MDR and IVDR - Proposal ongoing: https://health.ec.europa.eu/document/download/25e7ea7c-cab3-40cf-86d9-d11f5e7744d8_en?filename=md_com_2025-1023_act_en.pdf  -  https://ec.europa.eu/commission/presscorner/api/files/document/print/en/qanda_25_3078/QANDA_25_3078_EN.pdf  -  https://ec.europa.eu/commission/presscorner/api/files/attachment/882087/FACTSHEET%20medical%20devices%20final%20(1).pdfTeam NB Position Paper on Annex VII - Not agreeing all EU Proposal: https://www.team-nb.org/wp-content/uploads/2025/12/Team-NB-PositionPaper-Annex-VII-V1-20251216.pdfMDCG 2025-9 Learn Breakthrough Devices BtX - Guidance for innovative products: https://health.ec.europa.eu/document/download/edca94c7-62ab-4dd5-8539-2b347bd14809_en?filename=mdcg_2025-9.pdfInfographic: https://www.linkedin.com/posts/melazzouzi_medtech-mdr-ivdr-activity-7414590943179202560-jbxH?utm_source=share&utm_medium=member_desktop&rcm=ACoAAABZ07ABDocaBMTLJo8bsl8V3bgNSBIiZuIMDCG 2025-10 on PMS - Learn how to do it with this guidance: https://health.ec.europa.eu/document/download/a9ad86b7-1b8e-4bae-beb4-48b2b3ed2f05_en?filename=mdcg_2025-10_en.pdfNotified Body Malta Conformity Assessment - 52nd Notified Body for MDR: https://webgate.ec.europa.eu/single-market-compliance-space/notified-bodies/notifications?organizationRefeCd=SIMS_INPUT_282916&filter=notificationStatusId:1  ServicesEasyIFU - Manage your eIFU and Labels: https://easyifu.com SwitzerlandSwissdamed registration deadline - July 1st 2026: https://www.swissmedic.ch/swissmedic/en/home/medical-devices/medizinprodukte-datenbank/swissdamed-informationen/frist-produktregistrierung-in-swissdamed.html - https://swissdamed-webinar.ch/#E402A0UKMHRA Price changing -: More cost for manufacturers: https://www.gov.uk/guidance/register-medical-devices-to-place-on-the-market#fees RoWFDA: How to use Real World Evidence - Guidance Document offered: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devicesAustralia: Preparing for UDI and AusUDID - Checklist for preparation available: https://www.tga.gov.au/sites/default/files/2025-12/preparing-for-udi-in-australia-checklist_0.pdf PodcastPodcast Nostalgia - What was discussed lastly: Episode 367 - From Engineer to Clinical Evaluation Expert - Florian Tolkmitt: https://podcast.easymedicaldevice.com/367-2/Episode 368 - Simplifying EU MDR IVDR with Adam Isaacs Rae: https://podcast.easymedicaldevice.com/368-2/Episode 369 - Last Podcast of the Year: https://podcast.easymedicaldevice.com/369-2/Episode 370 - Verification & Validation with Aaron Joseph: https://podcast.easymedicaldevice.com/370-2/

Today my guest is Renuka Sane who is the managing director of Managing Director of Trustbridge. An institution that seeks to improve India's business environment by improving the rule of law. Renuka was a member of many expert committees including: the Task Force of Experts set up by the Employees Provident Fund Organisation; the research team of the Bankruptcy Legislative Reforms Commission; the Pension Advisory Committee of the Pension Fund Regulatory Development Authority; and the Working Group on personal insolvency at the Insolvency and Bankruptcy Board of India. She received a Ph.D. in Economics from the University of New South Wales.  We talked about the old, new, and unified pension scheme and related reforms over the last few decades in India, India's broader financial regulation framework, separation of powers in regulatory authorities, the way regulatory orders are written, and much more.  Recorded December 17th, 2025. Read a full transcript enhanced with helpful links. Learn more about The 1991 Fellowship. Connect with Ideas of India Follow us on X Follow Shruti on X Follow Renuka on X Click here for the latest Ideas of India episodes sent straight to your inbox. Timestamps (00:00:00) - The 1991 Fellowship (00:01:09) - Intro (00:02:49) - India's Pension System (00:35:42) - Private Sector Pension Schemes (01:06:28) - Regulatory Orders (01:24:03) - Improving Transparency at the Reserve Bank of India (01:34:57) - Outro  

The Transformation Ground Control podcast covers a number of topics important to digital and business transformation. This episode covers the following topics and interviews:   New Tech Laws of 2026, Q&A (Darian Chwialkowski, Third Stage Consulting) Legal Shifts and Regulatory Pressures in the ERP Space (Marcus Harris, Taft Law) Digital Transformation Mistakes that CFO's Often Make We also cover a number of other relevant topics related to digital and business transformation throughout the show.  

Today's blockchain and crypto news Bitcoin is up slightly at $91,977  Ethereum is up slightly at $3,131 And Binance Coin is up slightly at $908 Former NY Mayor Eric Adams accused of rug pull. BitGo files amended registration BitMine buys more ETH Blockchain Regulatory Certainty act introduced ###Gemini Card Disclosure: The Gemini Credit Card is issued by WebBank. In order to qualify for the $200 crypto intro onus, you must spend $3,000 in your first 90 days. Terms Apply. Some exclusions apply to instant rewards in which rewards are deposited when the transaction posts. This content is not investment advice and trading crypto involves risk. For more details on rates, fees, and other cost information, see Rates & Fees. The Gemini Credit Card may not be used to make gambling-related purchases.  ### For 40% off your order, head to Udacity.com/DCR and use code DCR. Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode 78: Outsourced Compliance with Fizza Khan, Silver Regulatory Associates Fizza Khan from Silver Regulatory Associates visits the Tokens of Wisdom Studio to enlighten us about all things compliance. From deciding when to engage an outsourced provider to the nuts and bolts of compliance policies and navigating SEC exams, Fizza shares the wisdom.  Key Points From This Episode: How does an outsourced compliance engagement work? Compliance policies – is it one size fits all, or are they custom to the adviser?What goes into compiling an effective set of policies?How are you involved in regulatory exams?When should a manager consider engaging outsourced compliance?How do you charge for your services? How should I choose the right outsourced compliance provider? What's the smartest thing a new fund manager can do?  Disclaimer: This show is for informational purposes only. Nothing presented here constitutes legal, investment or tax advice. The guests that join us share their considerable fund-related wisdom, but everything they share here is their personal opinion and for educational purposes only. On this show, they are speaking for themselves, and not for their employer or any affiliated entity. Tokens of Wisdom is produced by Dave Rothschild, partner at Cole-Frieman & Mallon LLP headquartered in San Francisco, California. For more information, visit https://colefrieman.com/ Links Mentioned in Today's Episode: Dave Rothschild - https://www.linkedin.com/in/davidcrothschild/Fizza Khan - https://www.linkedin.com/in/fizzakhan1/ Cole-Frieman & Mallon LLP - https://colefrieman.com/Silver - https://silverregulatoryassociates.com/    Music by Joe Ginsberg - https://www.instagram.com/thejoeginsbergFor any questions or comments, email: tow@colefrieman.com

Medical oncologist, geriatrician, and physician scientist GJ van Londen and Chief of Genetic and Genomic Medicine at the University of Pittsburgh School of Medicine Gerald Vockley discuss the article "FDA delays could end vital treatment for rare disease patients." GJ and Gerald explore the complex regulatory impasse where the U.S. Food and Drug Administration denied standard approval for elamipretide despite a positive advisory committee vote, creating a financial crisis that threatens to cut off supply for everyone. GJ shares his personal journey from treating cancer to living with primary mitochondrial myopathy, while the conversation emphasizes the critical need for the agency to use the flexibility granted by the Orphan Drug Act to save a treatment that has already proven its worth. Join us to understand the life-or-death stakes hidden behind administrative decisions. This episode is presented by Scholar Advising, a fee-only financial advising firm specializing in providing advice for DIY investors. If you want clear, actionable strategies and confidence that your financial decisions are built on objective advice without AUM fees or commissions, Scholar is designed for you. Physicians often navigate complex compensation structures, including W-2 income, 1099 work, production bonuses, and practice ownership. Scholar's highly credentialed advisors guide high-earners through decisions like optimizing investments for long-term tax efficiency and expert strategies for financial independence. Every recommendation is tailored to the financial realities physicians face. VISIT SPONSOR → https://scholaradvising.com/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Arrash Yasavoli discusses how you should jump on investing in bitoin in 2026! Arrash's path from data engineering at LinkedIn into quantitative trading, crypto, and building Glitch, a SaaS platform that gives broader access to advanced trading strategies gives a unique perspective into possible 2026 investing plans. We also talk Bitcoin's role as a potential store of value, the divergence between Bitcoin and altcoins, the growing importance of real utility and valuation in crypto projects, the rise of ETFs and stablecoins as bridges to mainstream adoption, and more. We discuss... Crypto's transition from a speculative and "scammy" perception toward broader legitimacy through regulation, ETFs, and institutional adoption. Bitcoin is increasingly viewed as a store of value similar to gold rather than a scalable transactional currency. Bitcoin's fixed supply and resilience through multiple market cycles were highlighted as key drivers of long-term investor confidence. Bitcoin's historical growth rates are unlikely to persist, with future returns likely slowing and volatility remaining high. The growing divergence between Bitcoin performance and stagnant altcoins was identified as a sign of increasing market maturity. Many altcoins from earlier cycles failed due to hype-driven models that never delivered real value. The current crypto cycle was compared to the post–dot-com bust era, where focus shifts from excitement to sustainable business models. Regulatory clarity, including frameworks for crypto and stablecoins, was viewed as a major catalyst for continued adoption. Whether investors should trade or hold crypto, with emphasis on patience and fundamentals over speculation. Future crypto valuation models were described as moving toward revenue, profitability, and clear value propositions. Arrash outlined his work on BitTensor, a blockchain designed to create and trade real digital commodities. Crypto's long-term value lies in practical applications that quietly use blockchain under the hood rather than hype-driven narratives. Today's Panelists: Kirk Chisholm | Innovative Wealth Barbara Friedberg | Barbara Friedberg Personal Finance Follow on Facebook: https://www.facebook.com/moneytreepodcast Follow LinkedIn: https://www.linkedin.com/showcase/money-tree-investing-podcast Follow on Twitter/X: https://x.com/MTIPodcast For more information, visit the show notes at https://moneytreepodcast.com/investing-in-bitcoin-in-2026-arrash-yasavolian-780 

PREVIEW FOR LATER TODAY REGULATORY HURDLES AND HIGH WINDS FUEL PALISADES FIREColleague Jeff Bliss, Pacific Watch. Jeff Bliss reports on the January 2025 Pacific Palisades fire, allegedly ignited by an arsonist and exacerbated by Santa Ana winds. Bliss notes that state regulations protecting a specific plant prevented fire crews from bulldozing underbrush, allowing embers to reignite and causing the catastrophe to rapidly expand.1919 PACIFIC PALISADES